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OBJECTIVE—Fulminant type 1 diabetes is characterized by the
rapid onset of severe hyperglycemia and ketoacidosis, with
subsequent poor prognosis of diabetes complications. Causative
mechanisms for accelerated -cell failure are unclear.
RESEARCH DESIGN AND METHODS—Subjects comprised
three autopsied patients who died from diabetic ketoacidosis
within 2–5 days after onset of fulminant type 1 diabetes. We
examined islet cell status, including the presence of enterovirus
and chemokine/cytokine/major histocompatibility complex
(MHC) expressions in the pancreata using immunohistochemical
analyses and RT-PCR.
RESULTS—Immunohistochemical analysis revealed the pres-
ence of enterovirus-capsid protein in all three affected pancreata.
Extensive inﬁltration of CXCR3 receptor–bearing T-cells and
macrophages into islets was observed. Dendritic cells were
stained in and around the islets. Speciﬁcally, interferon- and
CXC chemokine ligand 10 (CXCL10) were strongly coexpressed
in all subtypes of islet cells, including -cells and -cells. No
CXCL10 was expressed in exocrine pancreas. Serum levels of
CXCL10 were increased. Expression of MHC class II and hyper-
expression of MHC class I was observed in some islet cells.
CONCLUSIONS—These results strongly suggest the presence
of a circuit for the destruction of -cells in fulminant type 1
diabetes. Enterovirus infection of the pancreas initiates coex-
pression of interferon- and CXCL10 in -cells. CXCL10 secreted
from -cells activates and attracts autoreactive T-cells and
macrophages to the islets via CXCR3. These inﬁltrating autore-
active T-cells and macrophages release inﬂammatory cytokines
including interferon- in the islets, not only damaging -cells but
also accelerating CXCL10 generation in residual -cells and thus
further activating cell-mediated autoimmunity until all -cells
have been destroyed. Diabetes 58:2285–2291, 2009
F
ulminant type 1 diabetes is characterized by
abrupt onset of severe hyperglycemia and keto-
acidosis preceded by ﬂu-like symptoms including
fever, abdominal pain, and headache (1–3). Due
to the rushed clinical course in most cases, patients with
fulminant type 1 diabetes are sometimes untreated until
becoming comatose and/or entering a critical, life-threaten-
ing state (4). Endogenous insulin secretion is completely
abolished over time and diabetic microangiopathies develop
over a short duration (5,6). The mechanisms underlying the
aggressive and rapid destruction of -cells have remained
one of the major questions regarding this subtype of type 1
diabetes. However, in situ human data on affected islets and
pancreas and possible mechanisms have been completely
lacking for fulminant type 1 diabetes.
Viral infection with subsequent immunological mecha-
nisms represents one of the leading candidates for de-
struction of -cells in fulminant type 1 diabetes (3,7).
Some studies on the mouse model of lymphocytic chorio-
meningitis virus–induced type 1 diabetes have demon-
strated that islet -cells can be destroyed as follows:
within 1 day after virus infection, CXC chemokine ligand
10 (CXCL10) (8), a key chemoattractant for activated
T-cells and macrophages, is produced in -cells and se-
creted from islets (9). Activated T-cells bearing the recep-
tor for CXCL10, named CXCR3 (8), inﬁltrate and
accumulate in islets secreting CXCL10 (10). Accumulated
T-cells at the islets then destroy -cells through cell-
mediated mechanisms (11). With this mechanism, CXCL10
is necessary and sufﬁcient for accelerated T-cell response
with complete -cell destruction and resulting type 1
diabetes (10,12,13). We have recently found that serum
CXCL10 levels are increased at the onset of fulminant type
1 diabetes, suggesting a crucial role of the CXCL10-CXCR3
axis in the aggressive -cell destruction in this syndrome
(14). We therefore examined in situ status with regard to
enterovirus infection, CXCL10-CXCR3 axis, major histo-
compatibility complex (MHC) molecule expression, and
islet dysfunction in pancreata from patients with fulminant
type 1 diabetes who died due to diabetic ketoacidosis
within 2–5 days after outset of ﬂu-like symptoms. Our in
situ ﬁndings for affected pancreata provide new insights
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interventional strategies against human type 1 diabetes.
RESEARCH DESIGN AND METHODS
Patients
Case 1. A 14-year-old boy with type 1 diabetes in a ketoacidotic coma was
brought to our hospital and died 20 min later. He had developed headache and
high fever (38°C) 5 days earlier, with sudden onset of polyuria and
polydipsia 1 day before arrival. Blood glucose and hemoglobin A1C levels
were 70.3 mmol/l and 7.9%, respectively. Blood pH was 6.98 and plasma level
of 3-hydroxybutyrate was 64,000 mol/l. Serum C-peptide levels were 0.017
nmol/l. Negative results were obtained for autoantibody against GAD
(GADAb) and IA-2Ab. Serum elastase-1 and amylase levels were 4.4 and 8.9
times above the upper limit of normal, respectively. HLA-DRB1 and DQB1
genotypes in this patient were *0405/*0803 and *0401/*0601, respectively.
Case 2. A 25-year-old man with diabetic ketoacidosis arrived at the hospital
and died 40 min later. He had experienced symptoms of nausea and epigas-
tralgia for 2 days before becoming comatose. Blood glucose concentration
was 85.5 mmol/l, and A1C level was 5.1%. Blood gas analysis revealed acidosis
(pH 6.91). Serum elastase-1 concentration was 3.4 times the upper limit of
normal. Negative results were obtained for GADAb, IA-2Ab, and autoantibod-
ies against insulin. The patient’s HLA-DRB1 and DQB1 genotypes were
*0101/*0405 and *0501/*0401, respectively. This case was partly reported
previously (3).
Case 3. A 29-year-old man who collapsed with diabetic ketoacidosis was
admitted to our hospital and died 1 h after arrival. Two days earlier he had
experienced slight fever, nausea, and vomiting, followed the next day by
severe thirst and polyuria. On the day of admission, his family had found him
in a comatose state. Blood glucose level was 44.4 mmol/l, A1C level was 5.9%,
blood pH was 6.99, and pancreatic-isoamylase level was 40 times the upper
limit of normal. HLA-DRB1 and DQB1 genotypes in this patient were *0405/
*0901 and *0401/*0303, respectively.
Pancreatic tissues from 7 male patients with pancreatitis ([means  SD]
aged 61  20 years) and 10 nondiabetic male patients (aged 62  10 years)
with gastric carcinoma and had undergone partial pancreatectomy were used
as inﬂammation control subjects and nondiabetic control subjects, respec-
tively. In addition, pancreatic tissue from an autopsied patient (a 56-year-old
woman who died due to cerebral infarction) with slowly progressive insulin-
dependent type 1 diabetes (15) was also examined for presence of enterovirus
and CXCL10 expression in the pancreas. She had been treated with insulin and
had shown diminished urinary C-peptide secretion (1.1 nmol/day) and high
serum GADAb titer (12.5 units/ml [221.4 WHO units/ml]).
Detection of viral RNA in pancreatic tissues. RNAs were extracted from
two 5-m parafﬁn sections using a RecoverAll total nucleic acid isolation kit
(Ambion, Austin, TX) according to the protocol deﬁned by the manufacturer.
Nested RT-PCR targeting the 5 nontranslated region and VP1 region was
performed using the primers described previously (16–19). RT-PCR for
CXCL10 and interferon- was performed using the primer described previ-
ously (20,21).
Immunostaining, immunoﬂuorescent staining and morphometric anal-
yses. Methods for immunohistochemical and morphometric analyses have
been reported previously (22). In brief, serial sections (5 m) were cut from
5% formaldehyde-ﬁxed parafﬁn-embedded specimens, stained with hematox-
ylin and eosin, and then stained using indirect immunoperoxidase techniques
and double- or triple-immunoﬂuorescence techniques. Serial sections (5 m)
were deparafﬁnized, rehydrated, and subjected to antigen unmasking with
citrate buffer (pH 6.0). Sections were processed using an Envision	 kit (Dako,
Carpinteria, CA) or ABC Staining System (Santa Cruz Biotechnology, Santa
Cruz, CA), then visualized with diaminobenzidine tetrahydrochloride or
5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium chloride accord-
ing to the instructions from the manufacturer. Primary antibodies used in this
study were guinea pig anti-swine insulin (Dako), rabbit anti-human glucagon
(Dako), mouse monoclonal anti-enterovirus VP1 peptide (clone 5-D8/1; Novo-
castra, Newcastle Upon Tyne, U.K.; this antibody recognizes an epitope
mapped to residue 40–48 at the NH2-terminus of VP1 of enterovirus protein
[23] and reacts with 36 enteroviral serotypes [24]), mouse monoclonal
anti-CD8 (clone 144B; Dako), mouse monoclonal anti-CD4 (IF4; Novocastra),
mouse monoclonal anti-CD56 (clone CD564; Novocastra), rabbit monoclonal
anti-CD11c (EP1347Y; Abcam, Cambridge, U.K.), goat polyclonal anti-CXCL10
(R&D Systems, Minneapolis, MN), rabbit polyclonal anti-interferon- (Santa
Cruz Biotechnology), mouse monoclonal anti–interferon- (NYRhIFN-a; Ab-
cam), rabbit anti–2,5-oligoadenylate synthetase-like protein (HPA001474;
Sigma), mouse monoclonal anti–interferon- (clone 25718; R&D Systems),
mouse monoclonal anti-CXCR3/CD183 (clone 1C6; BD Bioscience, San Jose,
CA), mouse monoclonal anti-CD68 (clone PG-M1; Dako), mouse monoclonal
anti–HLA class-I (clone EMR8-5; Hokudo, Sapporo, Japan), and mouse mono-
clonal anti–HLA-DR (clone TAL.1B5; Dako).
For immunoﬂuorescent staining, sections were processed as described
above then incubated with 7-amino-4-methylcoumarin-3-acetic acid-, Texas
Red-, ﬂuorescein isothiocyanate– or Rhodamin Red–conjugated secondary
antibodies (all from Jackson ImmunoResearch Laboratories, West Grove, PA).
Stained sections were mounted with Vectashield (Vector Laboratories, Bur-
lingame, CA) and analyzed on an IX71 microscope (Olympus, Tokyo, Japan).
Phenotyping of mononuclear cells that had inﬁltrated islets was performed
using serial pancreas sections, and more than 23 islets from each patient and
control were examined. Immunostainings were carried out at least three times
for each section of the pancreas. Some pancreatic sections were processed
with isotype-matched control immunoglobulins (mouse IgG1, 
 [DAK-GO1;
Dako]; mouse IgG2a, 
 [DAK-GO5; Dako]; and rabbit IgG [X0903; Dako]) or in
the absence of primary antibody to conﬁrm the speciﬁcity of immunostaining.
We conﬁrmed that each primary antibody was speciﬁc for each antigen
(supplementary Fig. S1 [available at http://diabetes.diabetesjournals.org/
cgi/content/full/db09-0091/DC1). Sections were processed for immuno-
staining in the same run.
Morphometric analyses were performed using NIH Image software (http://
rsb.info.nih.gov/nih-image/). Photographs of histological specimens for each
case were taken at magniﬁcations of 200 and 400 for analysis. Twenty-two
images were examined for each patient compared with 34 for each control
subject. Percentage islet area was obtained by dividing the islet area by the
area of the entire section examined.
The percentage -cell area and percentage -cell area were calculated by
dividing each cell area by the area of the corresponding islet. -Cell volume
and -cell volume were calculated using percentage islet area multiplied by
percentage -cell area or percentage -cell area, respectively. According to
previous criteria (25), insulitis was deﬁned as inﬁltration of two or more
mononuclear cells into the islet.
Serum CXCL10 assay. We examined serum CXCL10 levels in two fulminant
type 1 diabetic patients (cases 1 and 2) using enzyme-linked immunosorbent
assay, as previously described (26). Serum samples were obtained on arrival
and stored at 80°C until assay.
Ethics. All procedures used in this study were approved by the ethical
committee of the University of Yamanashi.
Statistical analysis. Differences in variables between groups were compared
using the Student’s t test. Fisher’s exact test was used to compare the
frequencies of positive immunostainings. Values are expressed as means 
SD, unless otherwise mentioned.
RESULTS
Enterovirus in the pancreas. Immunohistochemical
staining showed the presence of enterovirus capsid pro-
tein (VP1) in the pancreas from all three patients with
fulminant type 1 diabetes (Fig. 1A–C). Some proportion of
islet cells was positive for VP1 (Fig. 1A and B). Some
VP1-positive acinar cells showed degenerating pathologi-
cal features (Fig. 1C). The number of VP1-positive cell
clusters on examined sections was 892/cm
2, 470/cm
2, and
752/cm
2 in cases 1, 2, and 3, respectively. No VP1-positive
cell clusters were found in the 10 nondiabetic control
subjects (P 
 0.004), 7 patients with pancreatitis (P 

0.008) (supplementary Fig. S2), or in the patient with
slowly progressive type 1 diabetes.
We were unable to detect the enterovirus sequence, and
we could not amplify 18S rRNA and/or glyceraldehyde
phosphate dehydrogenase (GAPDH) cDNAs from the pan-
creatic sections of diabetic patients, although we could
detect 18S rRNA and/or GAPDH sequences from control
pancreata. We therefore assumed that enterovirus RNAs
had already degraded.
CD8 T-cells, macrophages, and CD11c dendritic
cells in the pancreas. Marked mononuclear cell (MNC)
inﬁltration into islets (insulitis) and around islets (peri-
insulitis) was observed in all three cases with fulminant
type 1 diabetes (Fig. 2A–C). Frequency of insulitis per
examined islet was almost 100% in all three cases (Table
1). Islet volume and -cell volume were markedly de-
creased (Table 1). -Cell volume was decreased in case 1.
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ductal cells, were also surrounded by MNCs.
Predominant phenotypes of MNCs in islets with insulitis
were macrophages and CD8	 T-cells (Fig. 2B and C)
(Table 1). CD11c	 dendritic cells were detected in and
around the islet with or without -cells in cases 1 and 2
(Fig. 2D), while dendritic cell staining was less prominent
in case 3. CD11c	 dendritic cell inﬁltration into islets was
not observed in the 7 pancreatitis patients and 10 nondia-
betic control subjects. B-lymphocytes, CD4	 T-cells, and
NK cells were rare. VP1-positive pancreatic acinar cells
were surrounded predominantly by macrophages (supple-
mentary Fig. S3). In all three cases, MHC class II molecules
were expressed on some residual -cells (Fig. 2E). Mac-
rophages did not show positive immunostaining for insulin
(Fig. 2F), removing the possibility that macrophages with
phagocytosed insulin vesicles from damaged -cells rep-
resent MHC class II–expressing -cells (27). Some vascu-
lar endothelium surrounding or inside the islets showed
dilatation and enhanced expression of MHC class II mol-
ecules (Fig. 2G). MHC class I molecules were hyperex-
pressed on the pancreatic islet cells in three cases, while
the islet cells of nondiabetic control pancreas showed only
faint expression of MHC class I molecules in some islet
cells (Fig. 2H and I). We could not detect interferon- or
2,5-oligoadenylate synthetase–like protein on affected
pancreata from patients with fulminant type 1 diabetes
and control subjects, although these proteins represented
markers of recent virus infection in pancreata affected by
type 1 diabetes (28).
CXCL10 expressed in all islet cell subsets, which
were inﬁltrated by CXCR3 T-cells. Double immuno-
staining demonstrated CXCL10 expression in pancreatic
islets, while CXCR3-bearing MNCs that had inﬁltrated the
C
A B
FIG. 1. A: Immunohistochemical demonstration of enterovirus-associ-
ated VP1 antigen in pancreatic islets (brown, arrows). Cells with
shrunken and dark nuclei (arrows) suggestive of pyknosis, a sign of cell
death, were observed (400, case 1). B: Immunohistochemical staining
for glucagon in serial sections of (A)( 400). Comparing (A) and (B)
indicates enterovirus VP1 antigen residing on islet cells. C: Homoge-
neous staining for VP1 was observed in pancreatic acinar cell clusters
(brown) with shrunken and darkly staining nuclei suggestive of pykno-
sis (arrows) (400). (A high-quality digital representation of this
ﬁgure is available in the online issue.)
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FIG. 2. Mononuclear cell inﬁltration into islets with residual -cells
(A) (brown), macrophages (B) (brown), and CD8 T-cells (C)
(brown) (200, serial sections of case 1). D: Double immunoﬂuores-
cent staining for CD11c dendritic cells (red) and insulin (blue)
demonstrates that some dendritic cells surrounded and inﬁltrated into
islets (400, case 1). E: Double immunoﬂuorescent staining for insulin
(blue) and MHC class II antigen (green) demonstrates that some
residual -cells aberrantly express MHC class II molecules (light blue,
arrows) (400, case 1). F: Double immunostaining for CD68 macro-
phages (red) and insulin (blue). Insulin was not stained in macro-
phages (400, case 1). G: Double immunoﬂuorescent staining for MHC
class II molecules (green) and -cells (blue) demonstrates aberrant
expression of MHC class II molecules on vascular endothelium around
and within the islets (arrows) (400, case 1). H: Immunoﬂuorescent
staining demonstrates hyperexpression of MHC class I molecules
(green) on islet cells (200, case 1). I: Faint staining of MHC class I
molecules (green) were observed on some nondiabetic control islet-
cells (200). J: Double immunostaining of the pancreatic section
stained for CXCL10 (purple) and CXCR3 (brown). CXCR3-positive
cells have inﬁltrated islet cells expressing CXCL10 (200, case 1). (A
high-quality digital representation of this ﬁgure is available in the
online issue.)
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-Cells, -cells, and other subsets of islet cells expressed
CXCL10 in all three cases (Fig. 3A–D). The positive cells
for CXCL10 were observed in 96% (44 of 46), 100% (34 of
34), and 83% (31 of 38) of islets in case 1, case 2, and case
3, respectively. No CXCL10 expression was found in
pancreatic acinar or ductal cells, which were surrounded
by CD8	 T-cells and macrophages. Neither control pan-
creata nor that from the patient with slowly progressive
type 1 diabetes expressed CXCL10 in the islets or exocrine
pancreas (supplementary Figs. S4 and S5).
Coexpression of CXCL10 and interferon- in islet
cells. Interferon- was expressed in most -cells, -cells,
and other types of islet cells from the cases with fulminant
type 1 diabetes. Surprisingly, interferon- was coex-
pressed in CXCL10-positive islet cells (Fig. 4A–D). No
CXCL10 or interferon- was expressed on affected exo-
crine pancreas or nondiabetic pancreas. RT-PCR could not
TABLE 1
Results on morohometric analysis, frequency of insulitis, and phenotypic analysis on three autopsied pancreata from patients with
fulminant type 1 diabetes
Morphometric analysis
Frequency
of insulitis
Phenotype of MNCs
inﬁltrating islets
Islet
volume (%)
-Cell
volume (%)
-Cell
volume (%) %( n1/n2)
Macrophage
(%)
CD8	
T-cell (%)
Patient
Case 1 0.46 0.006 0.073 100 (34/34) 42.3 38.4
Case 2 0.94 0.129 0.350 100 (39/39) 38.5 34.2
Case 3 0.39 0.001 0.174 95 (21/22) 70.2 24.6
Mean value in patients 0.60  0.30* 0.045  0.073† 0.199  0.140 99 (94/95) 50.3  17.3 32.4  7.1
Mean value in nondiabetic control
subjects (n 
 10) 3.14  1.85 2.233  1.431 0.300  0.079 0 (0/747) — —
Data are means  SD, unless otherwise indicated. n1, number of the islets with insulitis; n2, number of the evaluated islets. *P  0.002; †P 
0.001.
C
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FIG. 3. Triple-immnoﬂuorescent staining for CXCL10 (A), insulin (B), and glucagon (C). A merged image (D) demonstrates expression of
CXCL10 on -cells (light blue) (case 2). A proportion of -cells (orange, arrowheads) and other types of islet cells (green) also express CXCL10
(400, case 2). (A high-quality digital representation of this ﬁgure is available in the online issue.)
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pancreas by fulminant type 1 diabetes. As we were unable
to amplify 18S rRNA or GAPDH cDNAs from pancreatic
sections of diabetic patients as mentioned above, we
assumed that CXCL10 and interferon- RNAs had already
degraded.
Serum CXCL10 levels. Serum CXCL10 levels in cases 1
and 2 were 563 pg/ml and 622 pg/ml, respectively. Serum
CXCL10 levels were 13.5 times (case 1) and 15.0 times
(case 2) higher than the mean value for healthy subjects
(26).
DISCUSSION
We demonstrated various novel ﬁndings in fulminant type
1 diabetes that have not previously been reported for
typical human type 1 diabetes (29–31). First, extensive
enterovirus infection with severe inﬁltration of MNCs into
both islets (insulitis) and the exocrine pancreas was
observed around VP1-positive cells (Fig. 1A–C) (supple-
mentary Fig. S3). Typical type 1 diabetic pancreas showed
mild to moderate insulitis, distributed in a patchy manner
throughout the pancreas (29,30), and VP1-positive cells
could not be found in the exocrine pancreas (31). How-
ever, Richardson et al. (32) recently reported a high
prevalence of VP1 in the islets of young patients with
recent-onset type 1 diabetes using the same monoclonal
antibody applied in our study. The VP1-positive pancreatic
endocrine and exocrine cells showed characteristic fea-
tures of cell damage, including shrunken and darkly
stained nuclei suggestive of pyknosis, which was reported
in Coxsackie virus–infected islets (31). Elevated serum
pancreatic enzyme levels and pathological changes ob-
served in virus-infected cells (Fig. 1C) (supplementary Fig.
S3) showed enterovirus-associated involvement of the
exocrine pancreas in this syndrome. Second, CXCL10 and
interferon- were extensively coexpressed in islet cells
(Fig. 4A–D). Most MNCs inﬁltrating into islets were either
CD8	 T-cells bearing the CXCL10 receptor, CXCR3, or
macrophages.
CXCL10 is a chemokine that is inducible by interferon-
and exerts key roles in the expansion and attraction of
autoreactive and antigen-speciﬁc T-cells (10,12). This ﬁnd-
ing of the coexpression of CXCL10 and interferon- in
-cells suggests the presence of a unique immunological
circuit for accelerating -cell destruction. The initial event
that trigged CXCL10 expression on islet cells may be
enteroviral infection of -cells and the exocrine pancreas
surrounding the islets (Fig. 1A–C). In vitro studies showed
that enterovirus infection of islet cells induced CXCL10
production within 1–2 days after infection (33,34). In our
patients, serum CXCL10 levels were elevated to 10 times
higher than levels in control subjects. CXCL10 from islet
cells will preferentially activate autoreactive T-cells via
CXCR3 and thus attract cells to the islets releasing islet-
speciﬁc antigen (10,12,13). The presence of activated
autoreactive T-cells reacting with insulin B9-23 peptide,
A B
C D
FIG. 4. Triple-immunoﬂuorescent staining for CXCL10 (A), insulin (B), and interferon- (C) in case 3. D: Merged image shows that residual
-cells express both CXCL10 and interferon- (arrows) (400, case 3). (A high-quality digital representation of this ﬁgure is available in the
online issue.)
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diabetes (35). Dendritic cells in the pancreas amplify
immune responses to tissue antigens along with T-cells
(36), thus contributing to rapid progression of -cell
failure. MHC class II molecules expressed on -cells and
dilated capillary endothelium around the islets (Fig. 2G)
and aberrantly expressed MHC class II molecules on the
islet cells will facilitate the “homing” process of activated
T-cells and macrophages to islets (37–39). Our preliminary
study examined the expression of another chemotactic
protein besides CXCL10, namely monocyte chemotactic
protein (MCP)-1. However, we failed to identify positive
staining for MCP-1 on the affected pancreas, so CXCL10
and associated immunological cascades were studied.
Chemoattracted autoreactive T-cells and macrophages
brought to the islets will secrete interferon- and other
inﬂammatory cytokines upregulating MHC class I mole-
cules (Fig. 2H) and further destroy islet cells expressing
CXCL10 (13,40). In such an extensively inﬂamed milieu
in the islets, -cells produce both CXCL10 and interfer-
on- in the same cell (Fig. 4A–D). Interferon- in -cells
disturbs the function and viability of those cells and
further accelerates CXCL10 generation and activation of
autoreactive CXCR3-bearing T-cells and macrophages.
These additional activated and accumulated T-cells and
macrophages in the islets again secrete inﬂammatory
cytokines including interferon-, inducing further
CXCL10 generation in -cells and CXCR3-mediated T-
cell activation. This vicious cycle will continue until
complete destruction of all -cells has been achieved.
The absence of expression of CXCL10 or interferon- in
islets of the patient with slowly progressive type 1
diabetes (supplementary Fig. S5) supports the concept
that CXCL10 and CXCR3 activation circuit represents a
unique mechanism of rapid -cell destruction in fulmi-
nant type1 diabetes.
Another unique ﬁnding in patients with fulminant type 1
diabetes was that both - and -cells in islets were
infected by enterovirus and expressed CXCL10 and inter-
feron-. In Coxsackie B4 enterovirus–induced type 1 dia-
betes, -cells are speciﬁcally involved (41). Impaired -cell
volume was observed in case 1 and has been reported in
long-standing patients with fulminant type 1 diabetes
(42). Inﬂammatory processes were observed in pancre-
atic exocrine tissues in our study, and pancreatic en-
zyme is speciﬁcally increased in fulminant type 1
diabetes (3,4). These ﬁndings suggest that enterovirus-
causing diabetes will display a wide diversity of tropism
from -cell-speciﬁc, as in cases of typical type 1 diabe-
tes (41), to other subsets of pancreatic endocrine and
exocrine cells, as in cases of fulminant type 1 diabetes.
The genetic bondage of the host may have inﬂuence on
virus potency or tropism. We have already reported
speciﬁc genetic backgrounds (i.e., HLA-DRB1*0405 and
HLA-DQB1*0401, which was possessed in our cases) for
this syndrome (43).
The present ﬁndings regarding the destruction of islet
endocrine cells provide new insights into strategies for the
treatment of fulminant type 1 diabetes. Development of
antagonists and neutralizing agents for interferon- and
the CXCL10/CXCR3 axis may represent one therapeutic
option. In an experimental animal model of type 1 diabe-
tes, neutralization of CXCL10 can cure virus-induced type
1 diabetes (44).
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